Chinese Competitors Aren't Eroding ASML's EUV Core Monopoly

ASML reported Q3 revenue of $13.06 billion, beating estimates of $11.68 billion and rising 55.2% year over year; GAAP EPS of $14.4761 also topped the $10.6598 consensus, partly due to a €509.7 million one-time investment gain. Planned EUV supply for 2027–28 is below customer demand, with orders sought for 2029–30 and price increases taking full effect from 2028. The article highlights execution, AI-capex, over-ordering and China export-control risks; the average analyst target of $2,145.58 implies about 27.97% upside from $1,676.69.

Analysis

ASML’s key valuation tension is no longer moat versus Chinese competition; it is whether scarce tool capacity converts into incremental shipments and durable margins quickly enough to justify the multiple. A sold-out order book can support pricing, but it also caps near-term revenue conversion: backlog is not a substitute for delivery cadence, and customer deposits reduce—but do not eliminate—the risk of pushouts. The reported EPS beat is a weak anchor for valuation because it includes a one-time investment gain; track operating earnings and free-cash-flow conversion instead.

Near term, the market is likely to price the next capacity disclosure and delivery evidence more than another demand affirmation. Over 1–3 months, the decisive checks are whether Q4 lands within guidance and whether management supplies credible 2027–28 capacity detail. Over 6–18 months, higher pricing and next-generation tool productivity could expand economics, while memory’s stronger growth makes orders more exposed to a cyclical pause than a logic-led mix would. TSM and other advanced-node customers benefit from the EUV moat but may face a practical ceiling on their own capacity additions if ASML deliveries slip.

Contrarian risk: consensus may treat “sold out” as unambiguously bullish, while constrained output can defer earnings and amplify downside if AI capex cools. China is a longer-horizon policy risk, not evidence of a near-term technical substitute; tighter controls could still remove demand before local tools become credible. Verify capacity, cancellations, and customer capex rather than relying on management claims about bottlenecks.

Key Decisions for Investors

• Avoid chasing ASML solely on backlog headlines. Consider a staged long only after the next capacity update demonstrates a credible shipment ramp; the catalyst is conversion of backlog into delivered systems, not further order commentary.
• For relative exposure, consider long ASML against a smaller short in a broad semiconductor-equipment basket such as SOXX, sized to limit broad AI-capex beta. This expresses the EUV scarcity premium, but is vulnerable if the market de-rates high-multiple semiconductor names together.
• Treat the 1–3 month capacity and earnings disclosures as the risk gate: reduce or exit the long if Q4 misses its stated revenue range, management lowers delivery expectations, or customer cancellations/pushouts emerge. A sustained deterioration in ASML gross margin would also challenge the pricing-power thesis.
• Watch AI-capex revisions and export-control changes over the next 6–18 months. A broad capex retrenchment or restrictions that materially reduce China sales would falsify the demand runway; quantify exposure using company guidance before adding risk.